Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
ID: 346136Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346136

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-106.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD," aimed at stimulating research on HIV/AIDS, particularly in relation to communication disorders affecting individuals living with HIV. This initiative encourages applications that address high-priority research areas outlined by the NIH Office of AIDS Research, focusing on aspects such as hearing, balance, taste, smell, voice, speech, and language, with an emphasis on low-risk clinical trials that do not require FDA oversight. The funding available through R21 Exploratory/Developmental Research Grants amounts to a total of $275,000 for a two-year project period, with applications due by January 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-106-Full-Announcement.html
    PAR-23-106.html
    The Department of Health and Human Services has issued a Funding Opportunity Announcement (FOA) titled "Advancing HIV/AIDS Research within the Mission of the NIDCD." This initiative, led by the National Institute on Deafness and Other Communication Disorders (NIDCD), aims to stimulate research focused on HIV/AIDS, particularly regarding communication disorders impacting individuals living with HIV (PLWH). The FOA encourages applications that address NIH's high-priority research areas related to hearing, balance, taste, smell, voice, speech, and language. Funding is available through R21 Exploratory/Developmental Research Grants, supporting low-risk clinical trials that do not require FDA oversight. Applications are due in May and September 2023, with an overall budget of up to $275,000 for a two-year project period. Eligible applicants include various research institutions, nonprofits, government entities, and foreign organizations. The FOA emphasizes multidisciplinary collaborations and innovative approaches to improve health outcomes for PLWH, addressing significant barriers in the field of communication disorders. Review criteria will focus on significance, investigator qualifications, innovation, approach, and environment, with successful applications likely focused on testing hypotheses that can influence clinical practice and public health strategies for managing HIV. This announcement reflects a commitment to integrating emerging research into actionable health improvements for affected populations.
    Similar Opportunities
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to communication disorders associated with HIV/AIDS. This initiative encourages innovative, hypothesis-driven research that addresses high-priority areas such as hearing, speech, and language, with a focus on low-risk clinical trials that do not require FDA oversight. Eligible applicants include a wide range of organizations, such as higher education institutions and community-based organizations, with funding available up to $499,999 per year for projects lasting up to five years. Interested parties should submit their applications by January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Early-Stage Dissemination and Implementation Research in Communication Disorders" under the R21 grant mechanism. This initiative aims to support early-stage research projects that enhance the dissemination and implementation of evidence-based innovations (EBIs) in areas such as hearing, speech, balance, taste, and language, with a focus on addressing barriers to adoption in clinical settings. The funding opportunity will provide approximately $1 million, with individual project budgets capped at $275,000 over a two-year period, and applications are due by October 12, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Multidisciplinary Studies of HIV/AIDS and Aging," inviting applications for research that explores the intersection of HIV and aging. The primary objectives of this grant are to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in individuals living with HIV, as well as to improve strategies for testing, preventing, and treating HIV and managing related health complications. This funding opportunity is significant for advancing health interventions for older adults affected by HIV, with eligible applicants including a wide range of institutions such as higher education entities, community organizations, and tribal governments. Interested parties should note that the application deadline is May 7, 2027, and can find further details and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-091.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.